BiotechTube

MK-3475 and BCG

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma

Conditions

High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma, Endoscopic Surgical Procedure, Transitional Epithelial Cells

Trial Timeline

Nov 30, 2017 → Jan 1, 2021

NCT ID
NCT03345134

About MK-3475 and BCG

MK-3475 and BCG is a phase 2 stage product being developed by Merck for High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03345134. Target conditions include High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma, Endoscopic Surgical Procedure, Transitional Epithelial Cells.

What happened to similar drugs?

6 of 20 similar drugs in High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma were approved

Approved (6) Terminated (7) Active (9)
✅Bunazosin + Doxazosin + ValsartinEisaiApproved
✅AliskirenNovartisApproved
✅Aliskiren and HCTZNovartisApproved
✅Aspirin 100 mg + PlaceboBayerApproved
✅Escitalopram + Placebo oral tabletLundbeckApproved
✅losartan potassium + Comparator: PlaceboOrganonApproved
❌Edoxaban + ASADaiichi SankyoPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03345134Phase 2Recruiting

Competing Products

20 competing products in High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
azenosertibZentalis PharmaceuticalsPhase 2
32
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase IIGT BiopharmaPhase 1/2
14
Sepantronium BromideCothera BiosciencePhase 2
29
Edoxaban + ASADaiichi SankyoPhase 3
32
olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3
36
Bunazosin + Doxazosin + ValsartinEisaiApproved
43
Pembrolizumab + Pemetrexed + AbemaciclibEli LillyPhase 1
21
DSP-0390Sumitomo PharmaPhase 1
33
dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets + placebo; abiraterone acetate tablets; prednisone tabletsJiangsu Hengrui MedicinePhase 1
36
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
44
SHR3680 + PlaceboJiangsu Hengrui MedicinePhase 3
47
Camrelizumab、Rivoceranib + CamrelizumabJiangsu Hengrui MedicinePhase 2
35
Mirvetuximab soravtansine + CarboplatinAbbViePhase 2
39
HHPG-19K InjectionJiangsu Hengrui MedicinePhase 3
32
Mirvetuximab SoravtansineAbbViePhase 2
42
Zibotentan/Dapagliflozin + DapagliflozinAstraZenecaPhase 2
42
AZD5718 IR tablet + AZD5718 oral suspension + Rosuvastatin tabletAstraZenecaPhase 1
29
Metoprolol Succinate + HydrochlorothiazideAstraZenecaPhase 3
40
Olaparib Pill + AZD6738AstraZenecaPhase 2
35
DAPA/MET XR + DAPA + MET XRAstraZenecaPhase 3
40